New milestone in breast cancer prevention claimed by Greenwich

US biopharma company Greenwich LifeSciences (Nasdaq: GLSI) has announced an 80% reduction in breast cancer recurrence from its ongoing Phase III clinical program, dubbed FLAMINGO-01, with GLSI-100, an immunotherapy specially designed to prevent recurrence in high-risk HER2+ breast cancer patients following the standard-of-care treatment.

The findings further validate its Phase IIb data, which demonstrated 80% reduction (or more) in metastatic breast cancer recurrence, measured over five years of follow-up, it noted.

Breast cancer affects every 1 in 8 women, with nearly 300,000 new cases diagnosed each year in the USA. According to the National Institutes for Health (NIH), HER2 is expressed at some level in nearly 75% of breast cancers, where recurrence is prevalent after surgery, and even with standard of care treatments. It becomes a death sentence for countless lives, but that’s about to change.